### Alert

Albumex® 4 is normally clear or slightly opalescent. If it appears to be turbid, it must not be used and the bottle should be returned unopened to the Australian Red Cross Blood Service. Albumin is not recommended as the initial resuscitating fluid in hypotensive infants. If the product has been stored in the refrigerator it should be allowed to reach room temperature before administration.

### Indication

Hypovolaemia/shock with or without hypoalbuminaemia

Plasma exchange [normal saline recommended]

### Action

Albumin is involved in the maintenance of colloid osmotic pressure, binding and transport of plasma compounds (bilirubin, bile acids, long-chain fatty acids, thyroxine, vitamin D, calcium, magnesium, copper, zinc), renders some potential toxins harmless, is a carrier of nitric oxide and affects pharmacokinetics of many drugs. Albumin 4% is approximately isotonic with osmolality 260 mOsm/kg and pH 6.7 to 7.3. The half-life of albumin is about 19 days.

### Drug Type

Plasma product, manufactured from human plasma collected by the Australian Red Cross Blood Service.

### Trade Name

Albumex® 4

### Presentation

Albumex® 4 50 mL (2 g albumin), 250 mL (10 g albumin) and 500 mL (20 g albumin) bottles. Each bottle contains Human Albumin 40 g/L, sodium 140 mmol/L, chloride 128 mmol/L and octanoate 6.4 mmol/L. Albumex® 4 contains trace amounts of aluminium (≤200 microg/L).

### Dosage/Interval

Hypovolaemia/shock

10 to 20 mL/kg over 10 to 60 minutes titrated to clinical response.

Plasma exchange [normal saline recommended]:

\[
Volume \text{ albumin } 4\% \ (mL) = \frac{total \ blood \ volume \times (observed \ PCV - desired \ PCV)}{observed \ PCV}
\]

Where total blood volume = 80 mL/kg; desired PCV = 0.55

Infusion rate to match 1:1 with the rate of removal of blood.

### Maximum daily dose

Intravenous

### Preparation/Dilution

Administer undiluted

1. If the product has been stored in the refrigerator it should be allowed to reach room temperature before administration.

2. Always record the name and batch number of the product in order to maintain a link between the patient and the batch of the product.

Dilution of Albumex® 20 to Albumin 4% in case of unavailability of albumin 4%

Albumex® 20 can be diluted to an iso-oncotic protein concentration (4 to 5% albumin) prior to administration. Dilute in the proportion of 1 mL of Albumex® 20 to 4 mL of crystalloid solution (sodium chloride 0.9% or glucose 5% or 10%). DO NOT dilute with water since the lower tonicity will lead to intravascular haemolysis.

### Administration

Intravenously over 10 to 60 minutes titrated to clinical response. Albumex® 4 is packaged in a glass bottle that must be vented during use. [1]

### Monitoring

Continuous cardiorespiratory and temperature observations.

### Contraindications

History of allergy to albumin.

### Precautions

Cardiac failure, pulmonary oedema or severe anaemia.

The sodium concentration in this product is 140 mmol/L. This should be noted when the product is used in patients requiring sodium restriction.

Administration of albumin can aggravate myocardial depression in patients with shock.

### Drug Interactions

Hypotension has been reported in patients given albumin who are on angiotensin converting enzyme (ACE) inhibitors. The addition of other medicines to Albumex® 4 has not been evaluated.

### Adverse Reactions

Allergic reactions.

Possible harms associated with albumin infusion in neonates include fluid overload (pulmonary oedema, impaired gas exchange, worsening oxygenation, chronic lung disease, patent ductus arteriosus, myocardial dysfunction especially for infants with birth asphyxia), neurological injury...
(cerebral oedema, intraventricular haemorrhage due to rapid bolus administration), salt loading and fluid retention.

<table>
<thead>
<tr>
<th>Compatibility</th>
<th>Glucose 5% and 10%, glucose-sodium chloride combination. [2]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incompatibility</td>
<td>Albumex® 4 should not be mixed with protein hydrolysates, amino acid solutions, solutions containing alcohol or solutions containing drugs that bind to albumin (e.g. calcium channel blockers, antibiotics and benzodiazepines).</td>
</tr>
<tr>
<td>Stability</td>
<td>Store below 30°C (Do not freeze). Protect from light. If the product has been stored in the refrigerator it should be allowed to reach room temperature before administration. Do not use if the solution has been frozen.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Special Comments</th>
<th>Evidence summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>References</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Original version Date: 22/07/2019</th>
<th>Author: ANMF Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current Version number: 1.0</td>
<td>Current Version Date: 22/07/2019</td>
</tr>
<tr>
<td>Risk Rating: Medium</td>
<td>Due for Review: 22/07/2024</td>
</tr>
</tbody>
</table>

**Authors Contribution**

<table>
<thead>
<tr>
<th>Original author/s</th>
<th>Evidence Review</th>
<th>Nursing Review</th>
<th>Pharmacy Review</th>
<th>ANMF Group contributors</th>
<th>Final content and editing review of the original</th>
<th>Electronic version</th>
<th>Facilitator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Srinivas Bolisetty</td>
<td>David Osborn</td>
<td>Eszter Jozsa</td>
<td>Jing Xiao, Michelle Jenkins</td>
<td>Nikkant Phad, Himanshu Popat, James Marceau</td>
<td>Ian Whyte</td>
<td>Cindy Chen, Ian Callander</td>
<td>Srinivas Bolisetty</td>
</tr>
</tbody>
</table>

This is a printed copy. Refer to the HNE Health PPG for the most up to date version.